Form 4: Zevra Therapeutics Director Thomas Anderson Reports Stock Purchase and Disposal

Director Thomas Anderson of Zevra Therapeutics reports purchasing $6.8065 worth of common stock and disposing of 20,000 shares.

Summary

• On July 16, 2024, Thomas Anderson, a director of Zevra Therapeutics, Inc. (ZVRA), reported a transaction involving the company's common stock.
• Anderson purchased 10,000 shares of common stock at a price of $6.8065 per share.
• Anderson also disposed of 20,000 shares.
• Following the reported transaction, Anderson still beneficially owns shares of Zevra Therapeutics.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders (officers, directors, and 10% owners) trade in their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company insiders as it can provide insights into their confidence in the company's prospects.

Key Dates